Scientific Reports Publishes Data Demonstrating VR Platform Produces Peak

Experiences, Ego Attenuation & Connectedness Comparable to Moderate Dose

Psychedelics

aNUma, Inc., a digital therapeutics company building virtual reality programs to address the global
mental health crisis, today, announced that Scientific Reports has published research demonstrating
technology like that behind aNUma’s VR platform can deliver peak experiences, ego attenuation,
and connectedness comparable to psychedelics. This study, written by Dr. David Glowacki and
colleagues, is the first of its kind to be published in a leading peer-reviewed journal.

San Rafael, CA May 30, 2022 --(PR.com)-- aNUma, Inc. (“aNUma”), a digital therapeutics company
building virtual reality programs to address the global mental health crisis, today, announced that
Scientific Reports (Nature Publishing Group) has published research demonstrating technology like that
behind aNUma’s VR platform can deliver peak experiences, ego attenuation, and connectedness
comparable to psychedelics. This study, written by Dr. David Glowacki and colleagues, is the first of its
kind to be published in a leading peer-reviewed journal demonstrating that some of the benefits of
psychedelics can be obtained in VR without the use of drugs.

The article, “Group VR experiences can produce ego attenuation and connectedness comparable to
psychedelics,” describes research involving 58 participants who joined the experiences as part of a
remote, citizen science experiment. Connecting from VR “nodes” located across the US, the UK, and
Europe, participants met virtually in groups of 3-6 participants for a 50-60-minute virtual journey, called,
Isness, that involved movement, meditation, music, and guided reflection. Following the VR journey,
participants complete 4 validated self-report scales. Results were compared to those seen in previously
published studies of psychedelics that used the same measures. The scales included measures of
community belongingness (Inclusion of Community in Self Scale and Communitas Scale), ego
diminishment (Ego Dissolution Inventory), and peak experience (MEQ-30 Mystical Experience
Questionnaire). Scores from this study were statistically indistinguishable from recently published studies
using moderate doses of psychedelics. Participants in the Isness experiences reported feeling closer to
other participants, feeling a diminished sense of ego, and having peak experiences as measured by the
MEQ during their VR journeys.

This research indicates that some of the benefits of psychedelics may be achievable without drugs, using
cutting-edge virtual reality technology. “We’re very excited about the possibilities of this technology for
allowing people to have peak experiences and dissolve their sense of self without drugs,” said Dr.
Glowacki, lead author and Researcher at the Centro Singular de Investigacíon en Technoloxías
Intelixentes in Santiago de Compestela, Spain.

Research on psychedelics has demonstrated benefits for treating mental health conditions, including
end-of-life distress and major depressive disorder. However, these drugs are not currently legal in most
places and have some side effects. If some of the benefits of psychedelics can be achieved without drugs,
using VR, these technologies could become an important tool in the effort to treat the global mental
health crisis. Dr. Glowacki has co-founded a company, called, aNUma (anuma.com), to commercialize

Page 1 of 4
PR.com Press Release Distribution Terms
the technology studied in this research. According to aNUma co-founder and CEO Gregory Roufa, “We
at aNUma are committed to bringing this technology into the world where it can help people with mental
health issues, such as end-of-life distress and depression.” aNUma has developed a propriety multi-user
VR system to deliver experiences like aNUma as digital therapeutics.

About aNUma
aNUma is pioneering the development of digital medicines to address the global mental health crisis. Our
technologies leverage the state-of-art of virtual reality computing and a deep understanding of the
neuroscience of transformational technologies. We are developing novel experiences to help individuals
and their loved ones cope with the distress that occurs at the end of life. We are also developing
group-based digital therapeutics to address the challenges of major depressive disorder at a global scale.
aNUma was co-founded by Gregory Roufa, a successful serial entrepreneur; Dr. Joe Hardy, a cognitive
psychologist with digital therapeutics experience; and Dr. David Glowacki, a leading researcher in VR
applied to scientific simulation. aNUma’s advisory board includes leading neuroscience researchers Dr.
Robin Carhartt-Harris and Dr. Adam Gazzaley from the University of California, San Francisco.

Page 2 of 4
PR.com Press Release Distribution Terms
Contact Information:
aNUma
Joe Hardy
415-691-0094
Contact via Email
anuma.com

Online Version of Press Release:

https://www.pr.com/press-release/862471

Page 3 of 4
PR.com Press Release Distribution Terms
 Page 4 of 4
PR.com Press Release Distribution Terms